India Market Research Reports: GBI Research

Wednesday, June 26, 2013

Market Report: Indian Pharmaceutical Market Outlook - Enhanced purchasing power, rural market penetration

MarketResearchReports.Biz announces addition of new report “Indian Pharmaceutical Market Outlook” to its database

GBI Researchs new report Indian Pharmaceutical Market Outlook Enhanced purchasing power, rural market penetration and expanded access to healthcare attracting Big Pharma investment provides in-depth analysis of the trends, issues and challenges facing the Indian pharmaceutical market. It is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Researchs team of industry experts. The Indian pharmaceutical industry grew from $0.8 billion in 1980 to $21.73 billion in 2010 and is expected to grow further as Multinational Companies (MNCs) enter the market. Although pharmaceutical giants such as GlaxoSmithKline (GSK) have been present in the market for years, the rising income of the middle-class population, changing patent laws, low-cost skilled labor and low-priced infrastructure in India have attracted other MNCs. With the current scenario, the market is expected to grow at a Compound Annual Growth Rate (CAGR) of 12% during the 20112015 period. Branded generics are expected to become more prevalent in India as many global players are planning to launch them after their patents expire.

To check out the table of contents, visit: http://www.marketresearchreports.biz/analysis-details/indian-pharmaceutical-market-outlook-enhanced-purchasing-power-rural-market-penetration-and-expanded-access-to-healthcare-attracting-big-pharma-investment

The once highly fragmented Indian pharmaceutical industry is undergoing strategic consolidations with the aim of emerging as a highly organized sector. With the inflow of MNCs R&D operations the industry will continue to experience a trend of M&A. Deals and acquisitions are set to continue due to low-cost infrastructure and labor as patent expiries and the thin pipelines of major companies will cause revenues to fall.

The Indian government has implemented various initiatives to increase insurance coverage and reduce healthcare costs, such as the National Rural Health Mission and Jan Aushadhi. A revised pricing policy was also proposed in 2011, which will increase government control to over 60% of drugs.

Rising income levels, changing disease patterns, increasing reach of healthcare, reduced out-of-pocket expenditure and growth of new products such as generics and biosimilars are expected to drive growth in the future.

Scope

Macroeconomic environment of the pharmaceutical industry in India, covering demographic analysis, drivers, and barriers
Important industry characteristics, looking at healthcare policies, regulations, distribution, pricing, taxation, spending, insurance and reimbursement
Market analysis of segments such as prescription medicines, biotechnology, over-the-counter medicines and Contract Research and Manufacturing Services (CRAMS)
Annualized market data from 2005 to 2010 for important therapeutic segments
Competitive profiling of five major domestic and international companies operating in the Indian pharmaceutical market
Analysis of licensing, partnership and M&A deals that took place between 2007 and 2011

To Buy The Copy of This Report Visit: http://www.marketresearchreports.biz/analysis/160069

Reasons to buy

Develop market-entry and market-expansion strategies by identifying the leading segments poised for strong growth
Device a more tailored country strategy through understanding key drivers of and barriers to the pharmaceutical market
Develop key strategic initiatives by understanding leading companies key focus areas
Accelerate and strengthen your market position by identifying key companies for M&A and strategic partnerships

About Us

MarketResearchReports.Biz is the most comprehensive collection of market research reports. MarketResearchReports.Biz services are especially designed to save time and money of our clients. We are a one stop solution for all your research needs, our main offerings are syndicated research reports, custom research, subscription access and consulting services. We serve all sizes and types of companies spanning across various industries.

Contact
M/s Sheela
90 Sate Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA – Canada Toll Free: 866-997-4948
Email: sales@marketresearchreports.biz
Website: http://www.marketresearchreports.biz/

Blog: http://mrrbiz.blogspot.com/

Monday, June 17, 2013

Market Report: Oncology Therapeutics Market in India to 2018 - Introduction of Market-Based Pricing to Fuel Price Wars and Intense Competition Among Domestic and Multinational Players

Oncology Therapeutics Market in India to 2018 - Introduction of Market-Based Pricing to Fuel Price Wars and Intense Competition Among Domestic and Multinational Players’, which provides in-depth analysis of the key therapeutic indications of oncology, breast cancer, colorectal cancer, prostate cancer, lung cancer and Non-Hodgkin’s Lymphoma (NHL), with forecasts until 2018. It also looks at treatment usage patterns and includes insights into the oncology R&D pipeline.

The Indian oncology therapeutics market for breast cancer, lung cancer, colorectal cancer, prostate cancer and NHL was estimated to be worth $153.3m in 2011, having grown at a Compound Annual Growth Rate (CAGR) of 12.7% from 2004. It is expected to reach $238.8m in 2018 at a CAGR of 6.5% from 2011. The slower growth in the forecast period is mainly due to the reduction in the price of leading marketed products for breast cancer, colorectal cancer, lung cancer and NHL after all 348 drugs on the National List of Essential Medicines (NLEM) are brought under price control regulations.

To Read the Complete Report with TOC Visit: http://www.marketresearchreports.biz/analysis-details/oncology-therapeutics-market-in-india-to-2018-introduction-of-market-based-pricing-to-fuel-price-wars-and-intense-competition-among-domestic-and-multinational-players

The limitations of the current market are unclear patent laws, restrictive pricing and reimbursement policies, ailing infrastructure, and insufficient government aid. Low patient affordability is also a major restraint, and one that reimbursement and insurance policies must address if the market is to develop in the future.

Scope

The report analyzes treatment usage patterns, market characterization, pipeline analysis, competitive landscape and key M&A trends in the breast cancer, colorectal cancer, prostate cancer, lung cancer and NHL markets.
The report includes:
Data and analysis for the oncology therapeutics market in India
Annualized market data for the oncology therapeutics market in India from 2004 to 2011, with forecasts to 2018
Key drivers and restraints that have had a significant impact on the market
The competitive landscape of the oncology therapeutics market in India
Key M&A activities and licensing agreements that have taken place in the Indian oncology therapeutics market

To Buy The Copy of This Report Visit: http://www.marketresearchreports.biz/analysis/165776

Reasons to Buy

The report will enhance your decision-making capability by allowing you to:

Align your product portfolio to the markets with high growth potential
Develop market-entry and market-expansion strategies by identifying the potential regions and therapeutic segments poised for strong growth
Devise a more effectively tailored country strategy through the understanding of key drivers and barriers in the oncology market
Develop key strategic initiatives by understanding the key focus areas and leading companies
Accelerate and strengthen your market position by identifying key companies for mergers, acquisitions and strategic partnerships